Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
Sai‐Hong Ignatius Ou(University of California, Irvine), Eunice L. Kwak(Massachusetts General Hospital), Christina T. Siwak-Tapp(University of California, Irvine), Joni Dy(University of California, Irvine), Kristin Bergethon(Massachusetts General Hospital), Jeffrey W. Clark(Massachusetts General Hospital), D. Ross Camidge(University of Colorado Cancer Center), Benjamin Solomon(Peter MacCallum Cancer Centre), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Yung‐Jue Bang(Seoul National University Hospital), Dong‐Wan Kim(Seoul National University Hospital), James G. Christensen(Pfizer (United States)), Weiwei Tan(Pfizer (United States)), Keith D. Wilner(Pfizer (United States)), Ravi Salgia(University of Chicago Medical Center), A. John Iafrate(Massachusetts General Hospital)
Cited by 439
Abstract
Related Papers
No related papers found
Powered by citation graph analysis